Patient Group Direction for PREDNISOLONE (Version 02) Valid From 1 October September 2019

Size: px
Start display at page:

Download "Patient Group Direction for PREDNISOLONE (Version 02) Valid From 1 October September 2019"

Transcription

1 Version Control This PGD has been agreed by the following organisations FCMS PDS Medical Doncaster CCG Lancashire CCGs including East Lancashire, Fylde and Wyre and North Lancashire CCGs Change history 31/07/17 V02 Review. No changes needed. 28/08/17 V02 Review. Adjustments to dose ranges. Clarification of advice on short courses/stopping abruptly. Minor editing changes. 18/09/17 V02 Adjusted age exclusions. Addition of further follow up advice. 28/08/2017 Page 1 of 8

2 CLINICAL CONTENT OF PATIENT GROUP DIRECTION Staff Characteristics Qualifications Specialist competencies or qualifications Continuing training and education Registered nurse, Paramedic practitioner, ECP (Paramedic) or Nurse practitioner Received training to undertake administration and supply of medicines under PGD. Has undertaken appropriate training to carry out clinical assessment of patient, leading to diagnosis. Also that such diagnosis requires treatment according to the indications listed in this PGD. The practitioner should be aware of any change to the recommendations for the medicine listed. It is the responsibility of the individual to keep up to date with continued professional development and to work within the limitations of individual scope or practice. Clinical Details Indication Treatment of exacerbations of asthma or COPD. Inclusion criteria Patients with the above indications. Exclusion criteria Hypersensitivity to prednisolone, corticosteroids or any constituent of the product. Pregnancy or breast feeding. Patients already taking the relevant corticosteroid dose that would be advised for management of the exacerbation. Systemically unwell with infection unless anti-infective therapy is also employed. Patients with ocular herpes simplex. Previous steroid induced psychosis or mental health adverse effects. Previous steroid myopathy. Severe renal or hepatic impairment. Active peptic ulceration. Active tuberculosis. Immunosuppressed patients. Active chickenpox or measles. Age under 2 years. Patients taking aldesleukin, amphotericin, etoposide, methotrexate, mifamurtide, retinoids, ritonavir. PGDs should be used only where appropriate, suitable and legal. PGDs should not be routinely used when an independent prescriber is available. Precautions Particular care is required when considering the use of systemic corticosteroids in patients with existing or previous history of severe affective disorders in themselves or in their first degree relatives. These would include depressive or manic-depressive illness and previous 28/08/2017 Page 2 of 8

3 Management of excluded patients Action for patients not wishing / unable to receive care under this PGD steroid psychosis. Diabetes mellitus, pre-diabetic states, or family history of diabetes: may increase blood glucose levels. Glaucoma or family history of glaucoma: may be precipitated or worsened. Hypertension or congestive heart failure: may increase BP or oedema. Epilepsy. Osteoporosis: increased fracture risk (although relevance of a single course unlikely to be significant). Recent myocardial infarction: risk of rupture. Hypothyroidism. Do not administer vaccines until sufficient interval has elapsed following corticosteroid use. Patients taking antihypertensives (raised BP), antiplatelets and NSAIDs (increased GI risks stop NSAID if possible), erythromycin (increased corticosteroid levels), isoniazid (reduced levels), rifamycins (reduced corticosteroid effect), coumarin anticoagulants (INR check required), hypoglycaemic (increased blood glucose), carbamazepine, phenytoin, phenobarbital, primidone, carbimazole (reduced corticosteroid levels), itraconazole (increased corticosteroid levels), ciclosporin (increased prednisolone levels), diuretics (antagonised effects), tetracyclines (possible raised intracranial pressure), antacids (co-administration reduces steroid availability). Consider if any indication for hospital referral: o See BTS/SIGN guideline for more information all patients with severe or life-threatening asthma. o See NICE/GOLD COPD guideline. Discuss with GP or Clinical Lead or refer. Make patient aware of risks and potential consequences of not taking medicine. Discuss any alternatives if available. Discuss alternative options with GP or Clinical Lead. Document discussion with patient. 28/08/2017 Page 3 of 8

4 Description of Treatment Name of medicine Prednisolone Formulation and route Oral tablets and soluble tablets Strength 5mg Dosage Adults with COPD: 30mg (6x 5mg tablets) immediately and then each morning for 7 days. Adults and children 12 years and over with asthma: 40mg (8x 5mg tablets) immediately and then each morning for at least 5 days. Children 1 month to 11 years with asthma: o If not currently taking oral corticosteroids: 1mg per kg bodyweight (maximum 40mg) immediately and then each morning for 3 days. o If currently already taking oral corticosteroids: 2mg per kg bodyweight (maximum 60mg) immediately and then each morning for 3 days. Repeated dose instructions Duration of treatment Quantity to supply Legal status Special precautions Adverse effects Short courses (up to 21 days use) may be stopped abruptly unless: Patient has received more than 40mg daily for more than 1 week. Patient is on maintenance oral corticosteroids. Patient has had repeated oral corticosteroid courses in the recent past. Patient has stopped maintenance oral corticosteroid treatment in the last year. Patients who have other reasons for potential adrenocortical insufficiency. Patients who have repeatedly taken doses in the evening. In these cases seek advice on how to wean off oral corticosteroids. See above See above Sufficient pre-packed boxes of 28, 30, 40 or 42 tablets to complete appropriate course POM Explain indications, contraindications and cautions (refer to BNF) Dyspepsia, abdominal distension, acute pancreatitis, oesophageal ulceration and candidiasis; musculoskeletal effects: muscle weakness, vertebral and long bone fractures, tendon rupture; endocrine effects: menstrual irregularities and amenorrhoea, hirsutism, weight gain, hypercholesterolemia, hyperlipidaemia, negative nitrogen and calcium balance, increased appetite; increased susceptibility to and severity of infection, reactivation of dormant tuberculosis; neuropsychiatric effects: psychological dependence, insomnia, increased intracranial pressure with papilledema in children (usually after withdrawal), aggravation of schizophrenia, aggravation of epilepsy; ophthalmic effects: glaucoma, 28/08/2017 Page 4 of 8

5 papilledema, posterior subscapular cataracts, corneal or scleral thinning and exacerbation of ophthalmic viral or fungal disease, increased intra-ocular pressure, exophthalmos; also impaired healing, petechiae, ecchymosis, facial erythema, suppression of skin test reactions, urticaria, hyperhidrosis, skin atrophy, bruising, telangiectasia, myocardial rupture following recent myocardial infarction, congestive heart failure, leucocytosis, hyperglycaemia, thromboembolism, nausea, malaise, hiccups, headache, vertigo. This is not a complete list. Refer to BNF or SPC (summary of product characteristics) for full information. Advice necessary All patients given a course of oral prednisolone for an exacerbation of asthma MUST be strongly advised to make a follow up appointment with their usual care team a need for prednisolone signifies a loss of asthma control which may require adjustment to ongoing treatment. Provide the patient with the manufacturer s Patient Information Leaflet. Advise on dose and administration with reference to the cautionary label information and give any further instructions to aid compliance. Advise on storage or expiry details and to dispose of any unused medicines appropriately. Give advice on practical self-care if appropriate, including management of likely symptoms (including fever management where appropriate). Make patient aware of potential adverse effects and the action to take if they occur. Provide appropriate worsening advice describing the range of signs and symptoms to monitor for and the action to take if they occur. Consider whether the provision of health promotion material is appropriate e.g. on smoking or lifestyle factors. Provide any advice relevant to the patient from the Precautions section above. Use of a steroid warning card if duration of treatment indicates. Ensure patient has supply of inhaled beta2 agonist, any preventative therapies and that inhaler technique is correct. Patients with asthma requiring nebulisation have had an exacerbation: o This normally mandates preventative therapy (e.g. with an inhaled corticosteroid) for a minimum of the next two years. o Refer back to own surgery for follow up management. Use as an opportunity to educate regarding correct asthma/copd care. Communicate the event promptly to the patient s own surgery so that they can take appropriate follow up steps Prescribing guidance Doncaster, East Lancashire, Fylde and Wyre and North Lancashire CCG local guidelines. Relevant NICE guidelines and advice from Clinical Knowledge Summaries. 28/08/2017 Page 5 of 8

6 Records and Follow Up Referral arrangements Inform GP as soon as possible. Advise if worsening or no improvement to seek further medical advice. Records to be kept Patient s name, address, date of birth and consent given. Contact details of GP (if registered). Diagnosis. Dose and form administered. Batch and expiry details. Advice given to patient (including side effects). Signature / name of staff who administered or supplied the medication. If relevant, signature / name of staff who removed / discontinued the treatment. Details of any adverse drug reaction and actions taken, including documentation in the patient s medical record. Referral arrangements (including self-care). Any serious side effects attributable to drug should be recorded and medicine management advised via yellow card system found in BNF. Follow up Advise follow up with GP/ Practice nurse. Patient Group Direction, organisation and individual authorisation signatures can be found on the managerial content sheet along with other non-clinical details relating to this patient group direction. 28/08/2017 Page 6 of 8

7 Patient Group Direction Owner Details of PGD owner FCMS (NW) Ltd Newfield House Vicarage Lane Blackpool FY4 4EW Patient Group Direction Authorisation Lead Doctor MANAGERIAL CONTENT OF PATIENT GROUP DIRECTION Lead Pharmacist Dr Jonathon Bundy Magnus Hird Lead Nurse Lead Paramedic Alison O Connor Organisational Authorisation for FCMS Organisational Authorisation for Doncaster CCG Suzy Layton Patient Group Direction Peer Review Reviewed by Wendy Lambert, Nurse Practitioner 28/08/2017 Page 7 of 8

8 Individual Authorisation BY SIGNING THIS PATIENT GROUP DIRECTION YOU ARE INDICATING THAT YOU AGREE TO ITS CONTENTS AND THAT YOU WILL WORK WITHIN IT. PGDs DO NOT REMOVE INHERENT PROFESSIONAL OBLIGATIONS OR ACCOUNTABILITY. IF THIS IS AN UPDATED OR REPLACEMENT PGD ENSURE THAT ALL OLDER VERSIONS ARE WITHDRAWN FROM USE WITH IMMEDIATE EFFECT. IT IS YOUR RESPONSIBILITY TO MAKE SURE YOU ARE USING THE CURRENT VERSION. NOTE TO AUTORISING MANAGERS: AUTHORISED STAFF SHOULD BE PROVIDED WITH AN INDIVIDUAL COPY OF THE CLINICAL CONTENT OF THIS PGD AND A PHOTOCOPY OF THE AUTHORISATION SHEET SHOWING THEIR AUTHORISATION. Name of Professional Signature Authorising Manager Date 28/08/2017 Page 8 of 8

Patient Group Direction for SALBUTAMOL INHALER (Version 02) Valid From 1 October September 2019

Patient Group Direction for SALBUTAMOL INHALER (Version 02) Valid From 1 October September 2019 Version Control This PGD has been agreed by the following organisations FCMS PDS Medical Doncaster CCG Lancashire CCGs including East Lancashire, Fylde and Wyre and North Lancashire CCGs Change history

More information

Patient Group Direction for GLUCAGON (Version 02) Valid From 1 October September 2019

Patient Group Direction for GLUCAGON (Version 02) Valid From 1 October September 2019 Version Control This PGD has been agreed by the following organisations FCMS Doncaster CCG Lancashire CCGs including East Lancashire, Fylde and Wyre and North Lancashire CCGs Change history 31/07/17 V02

More information

Patient Group Direction for LEVONELLE (Version 02) Valid From 1 October September 2019

Patient Group Direction for LEVONELLE (Version 02) Valid From 1 October September 2019 Version Control This PGD has been agreed by the following organisations FCMS PDS Medical Doncaster CCG Lancashire CCGs including East Lancashire, Fylde and Wyre and North Lancashire CCGs Change history

More information

Patient Group Direction for LIDOCAINE INJECTION (Version 02) Valid From 1 October September 2019

Patient Group Direction for LIDOCAINE INJECTION (Version 02) Valid From 1 October September 2019 Version Control This PGD has been agreed by the following organisations FCMS PDS Medical Doncaster CCG Lancashire CCGs including East Lancashire, Fylde and Wyre and North Lancashire CCGs Change history

More information

Patient Group Direction for PROCHLORPERAZINE (Version 02) Valid From 1 October September 2019

Patient Group Direction for PROCHLORPERAZINE (Version 02) Valid From 1 October September 2019 Version Control This PGD has been agreed by the following organisations FCMS PDS Medical Doncaster CCG Lancashire CCGs including East Lancashire, Fylde and Wyre and North Lancashire CCGs Change history

More information

Patient Group Direction for Doxycycline (Tetracycline) Version: 01 Start Date: October 2015 Expiry Date: October 2018

Patient Group Direction for Doxycycline (Tetracycline) Version: 01 Start Date: October 2015 Expiry Date: October 2018 THIS PATIENT GROUP DIRECTION HAS BEEN AGREED BY THE FOLLOWING ORGANISATIONS: CLINICAL COMMISSIONING GROUP: Doncaster CCG Lancashire North CCG Fylde & Wyre CCG East Lancashire CCG Change history Version

More information

Developed By Name Signature Date

Developed By Name Signature Date Patient Group Direction 2154 version 2.0 Administration / Supply of Prednisolone in Acute Asthma by Registered Practitioners employed by Torbay and South Devon NHS Foundation Trust Date of Introduction:

More information

Document Details. Ibuprofen 200mg tablets and Ibuprofen oral liquid 100mg in 5ml

Document Details. Ibuprofen 200mg tablets and Ibuprofen oral liquid 100mg in 5ml Title Document Details Patient Group Direction (PGD) Ibuprofen 200mg tablets and Ibuprofen oral liquid 100mg in 5ml Trust Ref No 1445-36348 Local Ref (optional) Main points the document The treatment of

More information

Developed By Name Signature Date

Developed By Name Signature Date Patient Group Direction 2210 version 1.0 Supply of Dexamethasone for the Prevention of Chemotherapy Induced Nausea and Vomiting by Registered Practitioners employed by Torbay and South Devon NHS Foundation

More information

patient group direction

patient group direction NAPROXEN v01 1/10 NAPROXEN PGD Details Version 1.0 Legal category Staff grades Approved by POM Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic) Emergency Care Practitioner (Nurse)

More information

Patient Group Direction Hepatitis A vaccine Version: Hepatitis A 2015 Start Date: 1 st July 2015 Expiry Date:30 th June 2018

Patient Group Direction Hepatitis A vaccine Version: Hepatitis A 2015 Start Date: 1 st July 2015 Expiry Date:30 th June 2018 Patient Group Direction Hepatitis A vaccine Version: Hepatitis A 2015 Start 1 st July 2015 Expiry 30 th June 2018 THIS PATIENT GROUP DIRECTION HAS BEEN AGREED BY THE FOLLOWING ORGANISATIONS: BLACKPOOL

More information

THIS PATIENT GROUP DIRECTION HAS BEEN AGREED BY THE FOLLOWING ORGANISATIONS:

THIS PATIENT GROUP DIRECTION HAS BEEN AGREED BY THE FOLLOWING ORGANISATIONS: Patient Group Direction for Pneumococcal polysaccharide vaccine VERSION: PNEUMOCOCCAL POLY-2013.1 (Pneumovax II ) Start 1 st May 2013 Expiry 30 th April 2015 THIS PATIENT GROUP DIRECTION HAS BEEN AGREED

More information

Patient Group Direction for Combined Hepatitis A & B vaccine Version: Hep A + B Start Date: 1 st January 2014 Expiry Date: 31 st December 2015

Patient Group Direction for Combined Hepatitis A & B vaccine Version: Hep A + B Start Date: 1 st January 2014 Expiry Date: 31 st December 2015 Patient Group Direction for Combined Hepatitis A & B vaccine Version: Hep A + B 2014.1 Start 1 st January 2014 Expiry 31 st December 2015 THIS PATIENT GROUP DIRECTION HAS BEEN AGREED BY THE FOLLOWING ORGANISATIONS:

More information

Patient Group Direction for Varicella vaccine Version: Varicella Start Date: 1 st May 2014 Expiry Date: 30 th April 2017

Patient Group Direction for Varicella vaccine Version: Varicella Start Date: 1 st May 2014 Expiry Date: 30 th April 2017 Patient Group Direction for Varicella vaccine Version: Varicella 2014.1 Start Date: 1 st May 2014 Expiry Date: 30 th April 2017 THIS PATIENT GROUP DIRECTION HAS BEEN AGREED BY THE FOLLOWING ORGANISATIONS:

More information

Patient Group Direction for Varicella vaccine Version: Varicella Start Date: 1 st April 2016 Expiry Date: 31 st March 2019

Patient Group Direction for Varicella vaccine Version: Varicella Start Date: 1 st April 2016 Expiry Date: 31 st March 2019 Patient Group Direction for Varicella vaccine Version: Varicella 2016.1 Start Date: 1 st April 2016 Expiry Date: 31 st March 2019 THIS PATIENT GROUP DIRECTION HAS BEEN AGREED BY THE FOLLOWING ORGANISATIONS:

More information

Patient Group Direction for Rotavirus vaccine Version: ROTAVIRUS (Rotarix ) Start Date: 1 st July 2013 Expiry Date:30 th June 2015

Patient Group Direction for Rotavirus vaccine Version: ROTAVIRUS (Rotarix ) Start Date: 1 st July 2013 Expiry Date:30 th June 2015 Patient Group Direction for Rotavirus vaccine Version: ROTAVIRUS-2013. 1 (Rotarix ) Start 1 st July 2013 Expiry 30 th June 2015 THIS PATIENT GROUP DIRECTION HAS BEEN AGREED BY THE FOLLOWING ORGANISATIONS:

More information

patient group direction

patient group direction ASPIRIN v01 1/8 ASPIRIN PGD Details Version 1.0 Legal category P Staff grades Approved by Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic) Emergency Care Practitioner (Nurse)

More information

Document Details. Patient Group Direction

Document Details. Patient Group Direction Document Details Title Patient Group Direction (PGD) Salbutamol Aerosol Inhaler and salbutamol Nebulised Solution Trust Ref No 1569-34313 Local Ref (optional) Main points the document Treatment of acute

More information

CLINICAL CONTENT OF PATIENT GROUP DIRECTION FOR PNEUMOCOCCAL CONJUGATE VACCINE (Prevenar 13 )

CLINICAL CONTENT OF PATIENT GROUP DIRECTION FOR PNEUMOCOCCAL CONJUGATE VACCINE (Prevenar 13 ) Patient Group Direction for Pneumococcal Conjugate Vaccine (Prevenar 13 ) Version: PNEUMOCOCCAL CONJUGATE 2014.1 Start 1 st February 2014 Expiry 31 st January 2017 THIS PATIENT GROUP DIRECTION HAS BEEN

More information

PRESCRIBING INFORMATION

PRESCRIBING INFORMATION PRESCRIBING INFORMATION Pr FLORINEF (fludrocortisone acetate) 0.1 mg Tablets Mineralocorticoid for adrenal insufficiency Paladin Labs Inc. Date of Preparation: 6111 Royalmount Avenue, Suite 102 May 1,

More information

Patient Group Direction for the supply and/or administration of Ibuprofen 400mg tablets to patients attending NHS Borders services

Patient Group Direction for the supply and/or administration of Ibuprofen 400mg tablets to patients attending NHS Borders services Patient Group Direction for the supply and/or administration of Ibuprofen 400mg tablets to patients attending NHS Borders services This document authorises the supply and/or administration of Ibuprofen

More information

patient group direction

patient group direction ACICLOVIR v01 1/8 ACICLOVIR PGD Details Version 1.0 Legal category Staff grades Approved by POM Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic) Emergency Care Practitioner (Nurse)

More information

Change history Version number Change details Date Updated for National ACWY programme to be implemented August June 2015.

Change history Version number Change details Date Updated for National ACWY programme to be implemented August June 2015. Patient Group Direction for Conjugate Meningococcal ACWY vaccine Version: MEN ACWY CONJUGATE 2015.1 Start 1 st August 2015 Expiry 31 st July 2018 THIS PATIENT GROUP DIRECTION HAS BEEN AGREED BY THE FOLLOWING

More information

Document Details Patient Group Direction Hepatitis A vaccine (Havrix Monodose ) Trust Ref No Local Ref (optional) Main points the

Document Details Patient Group Direction Hepatitis A vaccine (Havrix Monodose ) Trust Ref No Local Ref (optional) Main points the Document Details Title Patient Group Direction Hepatitis A vaccine (Havrix Monodose ) Trust Ref No 1506-41174 Local Ref (optional) Main points the Active immunisation against infection caused by Hepatitis

More information

Expiry Date: September 2009 Template Version: Page 1 of 7

Expiry Date: September 2009 Template Version: Page 1 of 7 GG&C PGD ref 2007/467 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: Inclusion criteria: Exclusion criteria:

More information

Package leaflet: Information for the patient. Dexametason Abcur 4 mg tablets. Dexamethasone

Package leaflet: Information for the patient. Dexametason Abcur 4 mg tablets. Dexamethasone Package leaflet: Information for the patient Dexametason Abcur 1 mg tablets Dexametason Abcur 4 mg tablets Dexamethasone Read all of this leaflet carefully before you start taking this medicine because

More information

for adults engaged with the Family Wellbeing Service Isle of Wight In Community Pharmacy for Isle of Wight Public Health Commissioned Services

for adults engaged with the Family Wellbeing Service Isle of Wight In Community Pharmacy for Isle of Wight Public Health Commissioned Services The supply of Champix (Varenicline) Tablets 500mcg and 1mg by registered community pharmacists for smoking cessation / management of nicotine withdrawal for adults engaged with the Family Wellbeing Service

More information

PRESCRIBING INFORMATION. (betamethasone sodium phoshate) Enema 5 mg/100 ml. Topical Corticosteroid

PRESCRIBING INFORMATION. (betamethasone sodium phoshate) Enema 5 mg/100 ml. Topical Corticosteroid PRESCRIBING INFORMATION Pr BETNESOL (betamethasone sodium phoshate) Enema 5 mg/100 ml Topical Corticosteroid Paladin Labs Inc. Date of revision: 100 Alexis Nihon Blvd, Suite 600 May 1, 2009 St Laurent,

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Prednicare Tablets 1 mg 2. QUALITATIVE AND QUANTITATIVE COMPOSITION mg per tablet Active: Prednisolone 1.0 Other ingredients:

More information

Document Details. Patient Group Direction

Document Details. Patient Group Direction Document Details Title Patient Group Direction (PGD) Hepatitis B Vaccine (Engerix ) Trust Ref No 1505-41182 Local Ref (optional) Main points the Immunisation against Hepatitis B document covers Who is

More information

ESCA: Cinacalcet (Mimpara )

ESCA: Cinacalcet (Mimpara ) ESCA: Cinacalcet (Mimpara ) Effective Shared Care Agreement for the Treatment of Primary hyperparathyroidism when parathyroidectomy is contraindicated or not clinically appropriate. Specialist details

More information

Developed By Name Signature Date

Developed By Name Signature Date Patient Group Direction 2156 version 2.0 Administration of Ipratropium 250mcg/ml Nebuliser Solution in Acute Asthma by Registered Practitioners employed by Torbay and South Devon NHS Foundation Date of

More information

PRESCRIBING GUIDANCE TACROLIMUS for the treatment of INFLAMATORY BOWEL DISEASE (IBD)

PRESCRIBING GUIDANCE TACROLIMUS for the treatment of INFLAMATORY BOWEL DISEASE (IBD) PRESCRIBING GUIDANCE TACROLIMUS for the treatment of INFLAMATORY BOWEL DISEASE (IBD) For the latest information on interactions and adverse effects, always consult the latest version of the Summary of

More information

Expiry Date: July 2009 Template Version: Page 1 of 7

Expiry Date: July 2009 Template Version: Page 1 of 7 Salbutamol nebules YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT NPGD2007/355 (supersedes 2004/177) Clinical Condition Indication: Inclusion

More information

patient group direction

patient group direction SALBUTAMOL v01 1/12 SALBUTAMOL PGD Details Version 1.0 Legal category Staff grades Approved by POM Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic) Emergency Care Practitioner

More information

patient group direction

patient group direction NITROFURANTOIN v01 1/12 NITROFURANTOIN PGD Details Version 1.0 Legal category Staff grades Approved by POM Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic) Emergency Care Practitioner

More information

Patient Group Direction For The Administration Of H1N1 (Swine Flu) vaccine

Patient Group Direction For The Administration Of H1N1 (Swine Flu) vaccine n Patient Group Direction For The Administration Of H1N1 (Swine Flu) vaccine October 2009 PGD version template-2009.1 Page 1 of 8 Rationale Patient Group Direction For The Administration Of H1N1 (Swine

More information

Prescribing Guidelines Prescribing arrangement for the management of patients transferring from Secondary Care to Primary Care

Prescribing Guidelines Prescribing arrangement for the management of patients transferring from Secondary Care to Primary Care Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire Healthcare NHS Foundation Trust Berkshire West Primary Care

More information

PATIENT GROUP DIRECTION. Oral (live attenuated) Typhoid Vaccine (Ty21a) (Vivotif )

PATIENT GROUP DIRECTION. Oral (live attenuated) Typhoid Vaccine (Ty21a) (Vivotif ) PATIENT GROUP DIRECTION Administration of: Oral (live attenuated) Typhoid Vaccine (Ty21a) (Vivotif ) By: Practice Nurses In: General Practice It is the responsibility of the professional working under

More information

Summary of Product Characteristics

Summary of Product Characteristics 1 NAME OF THE MEDICINAL PRODUCT Synacthen 250 micrograms/ml solution for injection. Summary of Product Characteristics 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Active Substance 250 micrograms of Tetracosactide.

More information

CONJUGATE MENINGOCOCCAL (ACWY) VACCINE

CONJUGATE MENINGOCOCCAL (ACWY) VACCINE Cumbria & Lancashire Vaccine PGD Group ADVISORY INFORMATION FOR USE WITH PATIENT SPECIFIC DIRECTION OR INDIVIDUAL PRESCRIPTION SIGNED BY GP OR NON-MEDICAL PRESCRIBER. CONJUGATE MENINGOCOCCAL (ACWY) VACCINE

More information

PATIENT GROUP DIRECTION

PATIENT GROUP DIRECTION PATIENT GROUP DIRECTION FOR THE SUPPLY OF VARENICLINE (CHAMPIX ) TO ADULTS OVER 18 YEARS OF AGE BY COMMUNITY PHARMACISTS UNDER THE PUBLIC HEALTH SERVICE - SMOKING CESSSATION SERVICE IN NHS HIGHLAND THE

More information

patient group direction

patient group direction DIAZEPAM v01 1/9 DIAZEPAM PGD Details Version 1.0 Legal category Staff grades Approved by CD Benz POM Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic) Emergency Care Practitioner

More information

GG&C PGD ref no: 2016/1338 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT

GG&C PGD ref no: 2016/1338 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT GG&C PGD ref no: 2016/1338 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: For active immunisation of individuals

More information

Shared Care Agreement for Donepezil

Shared Care Agreement for Donepezil ESCA: for the treatment of Alzheimer s disease SECONDARY CARE SECTION TO BE COMPLETED BY INITIATING DOCTOR Patient s Name: Date of Birth: NHS Number: ESCA Date: One copy of information leaflet given to

More information

Job Title Name Signature Date. Director of Nursing Angela Wallace Signed Angela Wallace 30/6/2014

Job Title Name Signature Date. Director of Nursing Angela Wallace Signed Angela Wallace 30/6/2014 PATIENT GROUP DIRECTIONS FOR SUPPLY OF VARENICLINE (CHAMPIX ) BY AUTHORISED COMMUNITY PHARMACISTS WORKING IN FORTH VALLEY Protocol Number 445 Version 1 Date protocol prepared: June 2014 Date protocol due

More information

PATIENT GROUP DIRECTION (PGD) Supply of potassium iodide 65mg tablets to adults and children exposed to, or at risk of exposure to radioactive iodine

PATIENT GROUP DIRECTION (PGD) Supply of potassium iodide 65mg tablets to adults and children exposed to, or at risk of exposure to radioactive iodine PHE publications gateway number: PATIENT GROUP DIRECTION (PGD) Supply of potassium iodide 65mg tablets to adults and children exposed to, or at risk of exposure to radioactive iodine For the supply of

More information

PRESCRIBING GUIDANCE METHOTREXATE for the treatment of vasculitis

PRESCRIBING GUIDANCE METHOTREXATE for the treatment of vasculitis PRESCRIBING GUIDANCE METHOTREXATE for the treatment of vasculitis For the latest information on interactions and adverse effects, always consult the latest version of the Summary of Product Characteristics

More information

NHS Lothian Patient Group Direction Version: 007. Title: Levonorgestrel 1500mcg for Emergency Contraception

NHS Lothian Patient Group Direction Version: 007. Title: Levonorgestrel 1500mcg for Emergency Contraception PATIENT GROUP DIRECTION FOR THE ADMINISTRATION OF LEVORGESTREL 1500mcg FOR EMERGENCY CONTRACEPTION BY DESIGNATED HEALTHCARE PROFESSIONALS PROVIDING SEXUAL HEALTH SERVICES, UNSCHEDULED CARE SERVICES OR

More information

PATIENT GROUP DIRECTION SUPPLY of Emergency Hormonal Contraception To females under 25 years Levonelle 1500 (Levonorgestrel 1500 micrograms)

PATIENT GROUP DIRECTION SUPPLY of Emergency Hormonal Contraception To females under 25 years Levonelle 1500 (Levonorgestrel 1500 micrograms) PATIENT GROUP DIRECTION SUPPLY of Emergency Hormonal Contraception To females under 25 years Levonelle 1500 (Levonorgestrel 1500 micrograms) VALID FROM: 1 st July 2016 REVIEWED DATE: 30 th June 2019 This

More information

Clinical Condition Indication:

Clinical Condition Indication: GG&C PGD ref no: 2012/943 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: For active immunisation of individuals

More information

NHS Kent and Medway Medicines Management. Dronedarone (Multaq ) Shared Care Guideline For Prescribing

NHS Kent and Medway Medicines Management. Dronedarone (Multaq ) Shared Care Guideline For Prescribing NHS Kent and Medway Medicines Management Dronedarone (Multaq ) Shared Care Guideline For Prescribing Issue No: 2 Review Date (If Applicable): Accountable Officer: Heather Lucas Contact Details: 01233 618158

More information

Essential Shared Care Agreement Drugs for Dementia

Essential Shared Care Agreement Drugs for Dementia E098 Essential Shared Care Agreement Drugs for Dementia Please complete the following details: Patient s name, address, date of birth Consultant s contact details (p.3) And send One copy to: 1. the patient

More information

NHS Lothian Patient Group Direction PGD Number: 437 Version: 02. Title: Doxycycline: Chlamydia Sexual Health Services

NHS Lothian Patient Group Direction PGD Number: 437 Version: 02. Title: Doxycycline: Chlamydia Sexual Health Services PATIENT GROUP DIRECTION FOR THE SUPPLY OF DOXYCYCLINE FOR TREATMENT OF CHLAMYDIA, CONTACTS OF CHLAMYDIA OR CONTACTS OF NON-GONOCOCCAL URETHRITIS (NGU) PRESENTING WITH TREATMENT VOUCHER TO COMMUNITY PHARMACISTS

More information

Developed By Name Signature Date

Developed By Name Signature Date Patient Group Direction 2155 version 2.0 Administration / Supply of Inhaled Salbutamol in Asthma by Registered Practitioners employed by Torbay and South Devon NHS Foundation Trust Date of Introduction:

More information

Continence PGD transdermal oxybutynin Kentera patch 36mg

Continence PGD transdermal oxybutynin Kentera patch 36mg Continence PGD transdermal oxybutynin Kentera patch 36mg Patient group direction for the supply of transdermal oxybutynin Kentera patch 36mg to patients suffering from urinary frequency, urgency or incontinence

More information

PATIENT GROUP DIRECTION FOR THE SUPPLY OF VARENICLINE (Champix ) BY COMMUNITY PHARMACISTS

PATIENT GROUP DIRECTION FOR THE SUPPLY OF VARENICLINE (Champix ) BY COMMUNITY PHARMACISTS PATIENT GROUP DIRECTION FOR THE SUPPLY OF VARENICLINE (Champix ) BY COMMUNITY PHARMACISTS Version No: Draft 2 Please note this PGD has been approved by SWYFT Drugs and Therapeutic Committee this is an

More information

Essential Shared Care Agreement Drugs for Dementia

Essential Shared Care Agreement Drugs for Dementia Ref No. E052 Please complete the following details: Patient s name, address, date of birth Consultant s contact details (p.3) And send One copy to: 1. the patient s GP 2. put one copy in care plan 3. give

More information

patient group direction

patient group direction REVAXIS v01 1/12 REVAXIS (DIPHTHERIA, TETANUS AND POLIOMYELITIS (INACTIVATED) VACCINE (ADSORBED, REDUCED ANTIGEN(S) CONTENT)) PGD Details Version 1.0 Legal category Staff grades Approved by POM Paramedic

More information

GG&C PGD ref no: 2017/1427 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT

GG&C PGD ref no: 2017/1427 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT GG&C PGD ref no: 2017/1427 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: Active immunisation against rotavirus.

More information

PATIENT GROUP DIRECTION

PATIENT GROUP DIRECTION PATIENT GROUP DIRECTION Supply / Administration of: By: Pharmacists Azithromycin 250mg capsules for Chlamydia In: Community Pharmacy It is the responsibility of the professional working under this PGD

More information

Atomoxetine Effective Shared Care Agreement For Attention Deficit Hyperactivity Disorder (ADHD)

Atomoxetine Effective Shared Care Agreement For Attention Deficit Hyperactivity Disorder (ADHD) Atomoxetine Effective Shared Care Agreement For Attention Deficit Hyperactivity Disorder (ADHD) Section 1: Shared Care arrangements and responsibilities Section 1.1 Agreement to transfer of prescribing

More information

SHARED CARE PRESCRIBING GUIDELINE

SHARED CARE PRESCRIBING GUIDELINE WORKING IN PARTNERSHIP East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG, Surrey Heath CCG, North East Hampshire & Farnham CCG, Crawley CCG, Horsham & Mid-Sussex CCG SHARED

More information

Denosumab (Prolia 60 mg) Effective Shared Care Agreement For the treatment of Osteoporosis. Date: Date:

Denosumab (Prolia 60 mg) Effective Shared Care Agreement For the treatment of Osteoporosis. Date: Date: Denosumab (Prolia 60 mg) Effective Shared Care Agreement For the treatment of Osteoporosis Section 1: Shared care arrangements and responsibilities Section 1.1 Agreement for transfer of prescribing to

More information

Patient Group Direction for the Supply of Orlistat (Xenical) from Designated Community Pharmacies

Patient Group Direction for the Supply of Orlistat (Xenical) from Designated Community Pharmacies Patient Group Direction for the Supply of Orlistat (Xenical) from Designated Community Pharmacies Written by: Sheila Brown, Prescribing Adviser Date: September 2006 Reviewed by: Date: Ratified by: East

More information

Patient Group Direction for the Supply of Varenicline (Champix ) by Authorised Community Pharmacists

Patient Group Direction for the Supply of Varenicline (Champix ) by Authorised Community Pharmacists Patient Group Direction for the Supply of Varenicline (Champix ) This Patient Group Direction (PGD) is a specific written instruction for the supply of varenicline to groups of patients who may not be

More information

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Prednisolone Tablets BP 5 mg 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains Prednisolone 5 mg For excipients see 6.1

More information

EFFECTIVE SHARE CARE AGREEMENT. For the specialist use of LIOTHYRONINE for patients registered with a Dudley GP.

EFFECTIVE SHARE CARE AGREEMENT. For the specialist use of LIOTHYRONINE for patients registered with a Dudley GP. Specialist details Patient identifier Name Tel: EFFECTIVE SHARE CARE AGREEMENT For the specialist use of LIOTHYRONINE for patients registered with a Dudley GP. The aim of an Effective Shared Care Agreement

More information

Clinician Responsible for Training and Review: Emergency Department Consultant

Clinician Responsible for Training and Review: Emergency Department Consultant Patient Group Direction for the Supply of Salbutamol Inhaler to patients receiving treatment from NHS Borders Emergency Department/Out of Hours/Minor Injury Units This document authorises the supply or

More information

Prescribing Guidelines Prescribing arrangement for the management of patients transferring from Secondary Care to Primary Care

Prescribing Guidelines Prescribing arrangement for the management of patients transferring from Secondary Care to Primary Care Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire Healthcare NHS Foundation Trust Berkshire West Primary Care

More information

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

2. QUALITATIVE AND QUANTITATIVE COMPOSITION SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Hydrocortisone 20 mg Tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 20mg - Each tablet contains 20 mg of hydrocortisone. For the

More information

GG&C PGD ref no: 2016/1408 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT

GG&C PGD ref no: 2016/1408 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT GG&C PGD ref no: 2016/1408 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: Active immunisation against disease

More information

Administration of Short-Acting Beta-agonists for Acute Episodes of Moderate or Severe Asthma by Practice Nurses

Administration of Short-Acting Beta-agonists for Acute Episodes of Moderate or Severe Asthma by Practice Nurses 1. Clinical Condition or situation to which this Patient Group Direction applies Definition of clinical condition/situation Adults and children aged 2 years and above presenting with increasing symptoms

More information

SAMPLE. PGD Reviewed by: Chris Faldon, John Maloney, Tim Patterson, Adrian MacKenzie, Claire Stein

SAMPLE. PGD Reviewed by: Chris Faldon, John Maloney, Tim Patterson, Adrian MacKenzie, Claire Stein Patient Group Direction for the supply or administration of haemophilus influenzae type B and meningococcal conjugate vaccine to children requiring immunisation as part of the national childhood vaccination

More information

BNSSG Shared Care Guidance Please complete all sections

BNSSG Shared Care Guidance Please complete all sections NHS Bristol CCG NHS North Somerset CCG NHS South Gloucestershire CCG North Bristol NHS Trust University Hospitals Bristol NHS Foundation Trust Weston Area Health NHS Trust BNSSG Shared Care Guidance Please

More information

Shared Care Guidance. Vigabatrin

Shared Care Guidance. Vigabatrin North of Tyne Area Prescribing Committee Shared Care Guidance Vigabatrin July 2014 (Review date July 2016) This guidance has been prepared and approved for use in Newcastle, North Tyneside and Northumberland.

More information

HEPATITIS A + TYPHOID VACCINE

HEPATITIS A + TYPHOID VACCINE GG&C PGD ref no: 2017/1522 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: Indicated for active immunisation

More information

. AREAS OF RESPONSIBILITY FOR SHARED CARE

. AREAS OF RESPONSIBILITY FOR SHARED CARE SHARED CARE GUIDELINE FOR RILUZOLE IN THE MANAGEMENT OF MOTOR NEURONE DISEASE (MND) SPECIFICALLY AMYOTROPHIC LATERAL SCLEROSIS (ALS) INDICATION This shared care guideline has been prepared to support the

More information

NATIONAL PATIENT GROUP DIRECTION FOR SUPPLY OF PARACETAMOL ORAL SUSPENSION

NATIONAL PATIENT GROUP DIRECTION FOR SUPPLY OF PARACETAMOL ORAL SUSPENSION NATIONAL PATIENT GROUP DIRECTION FOR SUPPLY OF PARACETAMOL ORAL SUSPENSION 120 mg/5ml FOR PREVENTION OF POST IMMUNISATION FEVER FOLLOWING ADMINISTRATION OF MENINGOCOCCAL GROUP B VACCINE (BEXSERO ) BY AUTHORISED

More information

Name of Shared Care Agreement: AZATHIOPRINE/6-MERCAPTOPURINE: Oral immunomodulating drugs for inflammatory bowel disease. Reference number: 01/2008

Name of Shared Care Agreement: AZATHIOPRINE/6-MERCAPTOPURINE: Oral immunomodulating drugs for inflammatory bowel disease. Reference number: 01/2008 Name of Shared Care Agreement: AZATHIOPRINE/6-MERCAPTOPURINE: Oral immunomodulating drugs for inflammatory bowel disease. Reference number: 01/2008 Shared care agreement has been developed appropriately

More information

SOMATROPIN ( Genotropin, Humatrope, Norditropin,

SOMATROPIN ( Genotropin, Humatrope, Norditropin, Shared Care Guidelines DRUG: SOMATROPIN ( Genotropin, Humatrope, Norditropin, Saizen and Omnitrope ) (Adults) Introduction: Indication: Growth hormone deficiency in adults Dosage & administration: 150-300

More information

This document expires on Patient Group Direction No. VI 11

This document expires on Patient Group Direction No. VI 11 Patient Group Direction (PGD) for The Administration of Combined Inactivated Hepatitis A & Hepatitis B Vaccine (Twinrix adult, Twinrix paediatric) to Adults and Children over one year by Registered Nurses

More information

PATIENT GROUP DIRECTION PROCEDURE

PATIENT GROUP DIRECTION PROCEDURE PATIENT GROUP DIRECTION PROCEDURE Date approved 2 October 2015 Version 3 Approved by Yvette Oade, Chief Medical Officer Procedure Lead Clinical Governance Lead - Medicines Management Procedure Author Karen

More information

Package leaflet: Information for the patient. Plenadren 5 mg modified-release tablets Plenadren 20 mg modified-release tablets Hydrocortisone

Package leaflet: Information for the patient. Plenadren 5 mg modified-release tablets Plenadren 20 mg modified-release tablets Hydrocortisone Package leaflet: Information for the patient Plenadren 5 mg modified-release tablets Plenadren 20 mg modified-release tablets Hydrocortisone Read all of this leaflet carefully before you start taking this

More information

Hydroxychloroquine (Adults)

Hydroxychloroquine (Adults) Shared Care Guideline DRUG: Introduction: Contraindications & Warnings: Hydroxychloroquine (Adults) Indication: Rheumatoid arthritis and inflammatory osteoarthritis, discoid and systemic lupus erythematosus,

More information

Community Psychiatric Nurse. Consultant Psychiatrist, Substance Misuse Services

Community Psychiatric Nurse. Consultant Psychiatrist, Substance Misuse Services PATIENT GROUP DIRECTION (PGD) FOR THE ADMINISTRATION OF HEPATITIS A VACCINE (HAVRIX MONODOSE VACCINE) BY REGISTERED NURSES WORKING IN THE COMMUNITY SUBSTANCE MISUSE TEAMS Version Number : 2 Patient Group

More information

patient group direction

patient group direction DIAZEPAM (RECTAL) v01 1/8 DIAZEPAM (RECTAL) PGD Details Version 1.0 Legal category Staff grades Approved by POM Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic) Emergency Care

More information

GG&C PGD ref no: 2018/1603 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT

GG&C PGD ref no: 2018/1603 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT GG&C PGD ref no: 2018/1603 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: Inclusion criteria: Active immunisation

More information

Essential Shared Care Agreement: Lithium

Essential Shared Care Agreement: Lithium Ref No. E042 Essential Shared Care Agreement: Lithium Please complete the following details: Patient s name, address, date of birth Treatment (indication, dose regimen, brand name) Monitoring (proposed

More information

SHARED CARE GUIDELINE: Mycophenolate mofetil or mycophenolic acid for Maintenance of Immunosuppression after Kidney Transplantation in Adults

SHARED CARE GUIDELINE: Mycophenolate mofetil or mycophenolic acid for Maintenance of Immunosuppression after Kidney Transplantation in Adults NHS LINCOLNSHIRE in association with UNITED LINCOLNSHIRE HOSPITALS TRUST SHARED CARE GUIDELINE: Mycophenolate mofetil or mycophenolic acid for Maintenance of Immunosuppression after Kidney Transplantation

More information

Patient Group Direction for the Supply of Nitrofurantoin MR 100mg capsules

Patient Group Direction for the Supply of Nitrofurantoin MR 100mg capsules October 2016 Patient Group Direction for the Supply of Nitrofurantoin MR 100mg capsules This Patient Group Direction (PGD) is a specific written instruction for the supply and/or administration of nitrofurantoin

More information

Duration of treatment All DMARDs are long term treatments. Clinical benefit may take up to 6 months. 1

Duration of treatment All DMARDs are long term treatments. Clinical benefit may take up to 6 months. 1 Leflunomide Traffic light classification- Amber 1 Information sheet for Primary Care Prescribers Part of the Shared Care Protocol: Management of Rheumatological Conditions with Disease-Modifying Anti Rheumatic

More information

FACTSHEET CICLOSPORIN. Introduction. How does ciclosporin work? When is ciclosporin used?

FACTSHEET CICLOSPORIN. Introduction. How does ciclosporin work? When is ciclosporin used? Introduction Ciclosporin is a potent immunosuppressant drug that requires supervision by a specialised doctor such as a dermatologist. It was originally used to prevent organ rejection in transplant patients.

More information

PRODUCT LEAFLET: USER INFORMATION HYDROCORTISONE ERFA 20 MG TABLETS. Hydrocortisone

PRODUCT LEAFLET: USER INFORMATION HYDROCORTISONE ERFA 20 MG TABLETS. Hydrocortisone PRODUCT LEAFLET: USER INFORMATION HYDROCORTISONE ERFA 20 MG TABLETS Hydrocortisone Read this leaflet carefully before you start taking this medicine; it contains important information. - Keep this leaflet.

More information

PATIENT GROUP DIRECTIONS FOR SUPPLY OF VARENICLINE (CHAMPIX ) BY AUTHORISED COMMUNITY PHARMACISTS WORKING IN TAYSIDE

PATIENT GROUP DIRECTIONS FOR SUPPLY OF VARENICLINE (CHAMPIX ) BY AUTHORISED COMMUNITY PHARMACISTS WORKING IN TAYSIDE PATIENT GROUP DIRECTIONS FOR SUPPLY OF VARENICLINE (CHAMPIX ) BY AUTHORISED COMMUNITY PHARMACISTS WORKING IN TAYSIDE GENERAL POLICY 2 PATIENT GROUP DIRECTIONS FOR SUPPLY OF VARENICLINE 4 STANDING ORDER

More information

INZITAN. Quantitative composition The active substances are: dexamethasone, lidocaine (hydrochloride), thiamine (hydrochloride) and cyanocobalamin.

INZITAN. Quantitative composition The active substances are: dexamethasone, lidocaine (hydrochloride), thiamine (hydrochloride) and cyanocobalamin. Read all of this leaflet carefully before you start taking this medicine - Keep this leaflet. You may need to read it again. - If you have further questions, please ask your doctor or your pharmacist.

More information

This document expires on Patient Group Direction No. VI 7

This document expires on Patient Group Direction No. VI 7 Patient Group Direction (PGD) for The Administration of Combined low-dose Diphtheria, Tetanus, and Inactivated Polio Vaccine (Revaxis ) to individuals aged over 10 years, by Registered Nurses employed

More information